Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

Read More Below

For Active, Mild to Moderate Ulcerative Colitis (UC)

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to
    salicylates or aminosalicylates or to any of the ingredients of Lialda.

See Full Safety Information

Formulary Coverage

Select a state below to see the top 5 results*, or manually select from all the plans within that state.

We can offer you localized results. Select your choice when prompted.

Step 1:

Select Plan Type

[Plan Name]

Close
Plan Name Status Copay/Co-Ins
Product Status Copay/Co-Ins
Plan Name Lialda  Asacol® HD Apriso® Delzicol®

Select Plan in [State]

Select Plan Type

Beginning with:

0 Plans selected

Formulary Coverage Key4,5

Close
  • Tier 1: These drugs are available at the lowest copay. Most commonly, these are generic drugs.
  • Tier 2: These drugs are available at a middle-level copay. Most commonly, these are "preferred" (on formulary) brand drugs.
  • Tier 3P: These drugs are available at a preferred copay. Most commonly used when Tiers 1 and 2 apply to preferred generic and non-preferred generic drugs, respectively.
  • Tier 3: These drugs are available at a higher-level copay. Most commonly, these are "non-preferred" brand drugs.
  • Tier 4: These drugs are available at a higher-level copay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
  • Tier >4: These drugs are available at a higher-level copay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
  • N/A: Not Available. Formulary data for this drug/health plan are not available.
  • NC: Not Covered. Drugs that are not covered by the plan.
  • PA: Prior Authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
  • QL: Quantity Limits. Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of drug that will be covered.
  • ST: Step Therapy. This restriction typically requires that certain criteria be met prior to approval for the prescription.
  • OR: Other Restrictions. Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

E-mail Results

Close

Name

*Required field

*E-mail Address

The e-mail address provided will be used only to send these results.

Thank you, your e-mail has been sent.

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda.
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported with products such as Lialda that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiating use of Lialda and periodically while on therapy. Exercise caution when using Lialda in patients with known renal dysfunction or a history of renal disease.
  • Mesalamine has been associated with an acute intolerance syndrome (3% of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from an exacerbation of ulcerative colitis. Symptoms include cramping, acute abdominal pain and bloody diarrhea, and sometimes fever, headache, and rash. Observe patients closely for worsening of these symptoms while on treatment. If acute intolerance syndrome is suspected, promptly discontinue treatment with Lialda.
  • Some patients who have experienced a hypersensitivity reaction to sulfasalazine may have a similar reaction to Lialda or compounds that contain or are converted to mesalamine. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported with Lialda and other mesalamine-containing medications. Caution should be taken when prescribing Lialda to patients with conditions predisposing them to the development of myocarditis or pericarditis.
  • There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine. Caution should be exercised when administering Lialda to patients with liver disease.
  • Pyloric stenosis or other organic or functional obstruction in the upper gastrointestinal tract may cause prolonged gastric retention of Lialda, which would delay mesalamine release in the colon.
  • Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection because of the similarity in the chromatograms of normetanephrine and mesalamine's main metabolite, N-acetylaminosalicylic acid (N-Ac-5-ASA). An alternative, selective assay for normetanephrine should be considered.
  • In clinical trials, the most common adverse reactions (incidence ≥2%) were ulcerative colitis, headache, flatulence, liver function test abnormality, and abdominal pain. Pancreatitis occurred in <1% of patients and resulted in discontinuation of therapy with Lialda.
  • The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of renal reactions. The concurrent use of mesalamine with azathioprine or 6-mercaptopurine can increase the potential for blood disorders.
  • Safety and effectiveness of Lialda in pediatric patients have not been established.

Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Please click here for Full Prescribing Information for Lialda (mesalamine).